p-Tau 217 Blood Test – A clinically advanced blood-based biomarker assay designed for early and accurate detection of Alzheimer’s disease. It offers high sensitivity and specificity for tau pathology, enabling non-invasive diagnosis and improved patient stratification. This test provides greater accessibility and reduced procedural burden compared to traditional CSF or imaging methods, supporting timely intervention and optimized patient management.

Alzheimer’s Disease (AD) is marked by amyloid-beta plaques and neurofibrillary tangles, causing progressive neuronal loss. Traditional diagnostic tools are costly and limited in accessibility, delaying diagnosis. Fluid biomarkers, such as the FDA-approved CSF Aβ42/40 test, have transformed AD diagnosis by detecting amyloid pathology. Blood-based biomarkers, especially p-Tau 217, offer a less invasive, more accessible option with superior specificity and sensitivity. Neurocode’s ALZpath Dx p-Tau 217 assay provides highly accurate prediction of AD pathology, enabling earlier diagnosis and improved patient care.